Sameer R Ghate1, Zhiyi Li2, Jackson Tang2, Antonio Reis Nakasato3. 1. Director, Health Economics and Outcomes Research, Novartis Oncology, East Hanover, NJ. 2. Partner, Asclepius Analytics, New York, NY. 3. Medical Director, Novartis Oncology.
Abstract
BACKGROUND: Immunotherapies and targeted therapies have drastically improved survival in metastatic melanoma, but they can cause a range of adverse events (AEs). Understanding the costs of these events would facilitate an accurate comparison of melanoma treatments. OBJECTIVE: To compare the costs and frequency of AEs associated with immunotherapy and with targeted therapy in elderly patients with metastatic melanoma. METHODS: We conducted a retrospective cohort study using Medicare claims data from 2011 to 2014. Patients included had to have ≥1 diagnoses of metastatic melanoma and ≥1 claims for an immunotherapy or targeted therapy. We compared the 30-day expenditures of patients with and without each AE using a generalized linear model to determine the incremental cost per AE in patients who received immunotherapy or targeted therapy. The baseline demographic and clinical differences were adjusted for using propensity score with inverse probability of treatment. We also compared the mean costs of AEs associated with immunotherapy and targeted therapy. RESULTS: A total of 844 patients were included in the study (mean age, 75 years; standard deviation, 14 years). The mean baseline Charlson Comorbidity Index score was 8.4, and 65% of the patients were male. The mean cost for AEs was highest for respiratory events (ie, $24,150). Gastrointestinal, respiratory, and hematologic AEs were more common in patients who received immunotherapy, whereas general and administration-site AEs and other AEs (eg, fatigue, infections, muscular weakness) were more frequent in patients who received targeted therapy. AE-related costs with immunotherapy were highest for gastrointestinal, respiratory, and pain-related AEs; AEs with targeted therapy were highest for cardiovascular and general and administration-site events. CONCLUSION: These findings suggest that incremental costs associated with treatment-related AEs among elderly patients with metastatic melanoma were substantial, but the risks for and costs of the various types of AEs differed by therapy. Understanding the risks for and costs of AEs associated with the various therapeutic options can inform treatment decision-making in elderly patients with metastatic melanoma.
BACKGROUND: Immunotherapies and targeted therapies have drastically improved survival in metastatic melanoma, but they can cause a range of adverse events (AEs). Understanding the costs of these events would facilitate an accurate comparison of melanoma treatments. OBJECTIVE: To compare the costs and frequency of AEs associated with immunotherapy and with targeted therapy in elderly patients with metastatic melanoma. METHODS: We conducted a retrospective cohort study using Medicare claims data from 2011 to 2014. Patients included had to have ≥1 diagnoses of metastatic melanoma and ≥1 claims for an immunotherapy or targeted therapy. We compared the 30-day expenditures of patients with and without each AE using a generalized linear model to determine the incremental cost per AE in patients who received immunotherapy or targeted therapy. The baseline demographic and clinical differences were adjusted for using propensity score with inverse probability of treatment. We also compared the mean costs of AEs associated with immunotherapy and targeted therapy. RESULTS: A total of 844 patients were included in the study (mean age, 75 years; standard deviation, 14 years). The mean baseline Charlson Comorbidity Index score was 8.4, and 65% of the patients were male. The mean cost for AEs was highest for respiratory events (ie, $24,150). Gastrointestinal, respiratory, and hematologic AEs were more common in patients who received immunotherapy, whereas general and administration-site AEs and other AEs (eg, fatigue, infections, muscular weakness) were more frequent in patients who received targeted therapy. AE-related costs with immunotherapy were highest for gastrointestinal, respiratory, and pain-related AEs; AEs with targeted therapy were highest for cardiovascular and general and administration-site events. CONCLUSION: These findings suggest that incremental costs associated with treatment-related AEs among elderly patients with metastatic melanoma were substantial, but the risks for and costs of the various types of AEs differed by therapy. Understanding the risks for and costs of AEs associated with the various therapeutic options can inform treatment decision-making in elderly patients with metastatic melanoma.
Authors: Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf Journal: N Engl J Med Date: 2012-06-04 Impact factor: 91.245
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman Journal: Lancet Date: 2012-06-25 Impact factor: 79.321
Authors: Grant A McArthur; Paul B Chapman; Caroline Robert; James Larkin; John B Haanen; Reinhard Dummer; Antoni Ribas; David Hogg; Omid Hamid; Paolo A Ascierto; Claus Garbe; Alessandro Testori; Michele Maio; Paul Lorigan; Celeste Lebbé; Thomas Jouary; Dirk Schadendorf; Stephen J O'Day; John M Kirkwood; Alexander M Eggermont; Brigitte Dréno; Jeffrey A Sosman; Keith T Flaherty; Ming Yin; Ivor Caro; Suzanne Cheng; Kerstin Trunzer; Axel Hauschild Journal: Lancet Oncol Date: 2014-02-07 Impact factor: 41.316
Authors: Bhakti Arondekar; Suellen Curkendall; Matthew Monberg; Beloo Mirakhur; Alan K Oglesby; Gregory M Lenhart; Nicole Meyer Journal: J Manag Care Spec Pharm Date: 2015-02
Authors: Caroline J Voskens; Simone M Goldinger; Carmen Loquai; Caroline Robert; Katharina C Kaehler; Carola Berking; Tanja Bergmann; Clemens L Bockmeyer; Thomas Eigentler; Michael Fluck; Claus Garbe; Ralf Gutzmer; Stephan Grabbe; Axel Hauschild; Rüdiger Hein; Gheorghe Hundorfean; Armin Justich; Ullrich Keller; Christina Klein; Christine Mateus; Peter Mohr; Sylvie Paetzold; Imke Satzger; Dirk Schadendorf; Marc Schlaeppi; Gerold Schuler; Beatrice Schuler-Thurner; Uwe Trefzer; Jens Ulrich; Julia Vaubel; Roger von Moos; Patrik Weder; Tabea Wilhelm; Daniela Göppner; Reinhard Dummer; Lucie M Heinzerling Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240
Authors: Carla Mamolo; Verna Welch; Roland B Walter; Joseph C Cappelleri; James Brockbank; Matthew Cawson; Chris Knight; Michele Wilson Journal: Pharmacoeconomics Date: 2020-11-25 Impact factor: 4.981
Authors: Dukagjin M Blakaj; Marcelo Bonomi; Majd Issa; Brett G Klamer; Nikol Mladkova; Georgios I Laliotis; Vidhya Karivedu; Priyanka Bhateja; Chase Byington; Khaled Dibs; Xueliang Pan; Arnab Chakravarti; John Grecula; Sachin R Jhawar; Darrion Mitchell; Sujith Baliga; Matthew Old; Ricardo L Carrau; James W Rocco Journal: BMC Cancer Date: 2022-07-14 Impact factor: 4.638
Authors: Náthali Felícia Mineiro Dos Santos Garrett; Ana Cristina Carvalho da Costa; Elaine Barros Ferreira; Giovanni Damiani; Paula Elaine Diniz Dos Reis; Christiane Inocêncio Vasques Journal: PLoS One Date: 2021-08-06 Impact factor: 3.240